AngioDynamics (ANGO) Expected to Announce Quarterly Earnings on Thursday

AngioDynamics (NASDAQ:ANGO) is expected to post its Q3 2026 results before the market opens on Thursday, April 2nd. Analysts expect the company to announce earnings of ($0.11) per share and revenue of $76.7670 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Thursday, April 2, 2026 at 8:00 AM ET.

AngioDynamics Price Performance

NASDAQ:ANGO opened at $11.37 on Wednesday. AngioDynamics has a 1-year low of $8.36 and a 1-year high of $13.99. The business has a 50 day moving average of $10.83 and a 200 day moving average of $11.55. The company has a market capitalization of $468.67 million, a price-to-earnings ratio of -16.97 and a beta of 0.48.

Institutional Investors Weigh In On AngioDynamics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Lazard Asset Management LLC acquired a new position in shares of AngioDynamics in the 4th quarter valued at about $139,000. Federated Hermes Inc. purchased a new position in AngioDynamics during the fourth quarter valued at approximately $149,000. Cerity Partners LLC lifted its holdings in AngioDynamics by 24.5% in the fourth quarter. Cerity Partners LLC now owns 14,310 shares of the medical instruments supplier’s stock valued at $184,000 after acquiring an additional 2,813 shares during the period. State of Wyoming boosted its position in AngioDynamics by 140.1% in the 4th quarter. State of Wyoming now owns 11,402 shares of the medical instruments supplier’s stock worth $146,000 after purchasing an additional 6,653 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in AngioDynamics in the 3rd quarter worth approximately $118,000. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Wall Street Zen downgraded AngioDynamics from a “buy” rating to a “hold” rating in a report on Sunday, December 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a report on Wednesday, January 21st. Finally, Zacks Research upgraded shares of AngioDynamics from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.33.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.